Cambridge Trust Co. Has $10.43 Million Stock Position in Novo Nordisk A/S (NYSE:NVO)

Cambridge Trust Co. lifted its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 0.5% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 100,857 shares of the company’s stock after purchasing an additional 525 shares during the quarter. Cambridge Trust Co.’s holdings in Novo Nordisk A/S were worth $10,434,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of NVO. Roundview Capital LLC grew its holdings in shares of Novo Nordisk A/S by 0.6% during the 1st quarter. Roundview Capital LLC now owns 18,803 shares of the company’s stock worth $2,088,000 after purchasing an additional 106 shares in the last quarter. BlackRock Inc. boosted its stake in Novo Nordisk A/S by 45.4% in the first quarter. BlackRock Inc. now owns 5,035,879 shares of the company’s stock valued at $559,235,000 after buying an additional 1,571,747 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in Novo Nordisk A/S by 0.9% in the first quarter. Dimensional Fund Advisors LP now owns 739,585 shares of the company’s stock valued at $82,131,000 after buying an additional 6,903 shares in the last quarter. Blair William & Co. IL boosted its stake in Novo Nordisk A/S by 12.7% in the first quarter. Blair William & Co. IL now owns 19,466 shares of the company’s stock valued at $2,136,000 after buying an additional 2,194 shares in the last quarter. Finally, Sei Investments Co. boosted its stake in Novo Nordisk A/S by 17.5% in the first quarter. Sei Investments Co. now owns 107,175 shares of the company’s stock valued at $11,913,000 after buying an additional 15,996 shares in the last quarter. 11.54% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the company. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a research note on Thursday. UBS Group assumed coverage on Novo Nordisk A/S in a research report on Tuesday, January 16th. They set a “neutral” rating on the stock. Morgan Stanley assumed coverage on Novo Nordisk A/S in a research report on Tuesday, January 23rd. They set an “overweight” rating and a $120.00 target price on the stock. Finally, BMO Capital Markets assumed coverage on Novo Nordisk A/S in a research report on Friday, April 12th. They set an “outperform” rating and a $163.00 target price on the stock. Two research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $133.60.

Novo Nordisk A/S Price Performance

NYSE NVO traded down $1.92 during trading on Thursday, reaching $122.61. The company’s stock had a trading volume of 2,080,701 shares, compared to its average volume of 4,870,547. The firm has a fifty day moving average of $126.28 and a 200 day moving average of $110.42. Novo Nordisk A/S has a one year low of $75.56 and a one year high of $138.28. The company has a debt-to-equity ratio of 0.19, a current ratio of 0.82 and a quick ratio of 0.64. The stock has a market capitalization of $550.22 billion, a PE ratio of 45.51, a P/E/G ratio of 2.06 and a beta of 0.41.

Novo Nordisk A/S (NYSE:NVO) last released its earnings results on Wednesday, January 31st. The company reported $0.71 EPS for the quarter, beating analysts’ consensus estimates of $0.66 by $0.05. The company had revenue of $9.51 billion during the quarter, compared to analysts’ expectations of $9.14 billion. Novo Nordisk A/S had a return on equity of 90.36% and a net margin of 36.03%. Analysts expect that Novo Nordisk A/S will post 3.33 EPS for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The business also recently disclosed a Semi-Annual dividend, which was paid on Tuesday, April 2nd. Shareholders of record on Monday, March 25th were paid a dividend of $0.664 per share. This is a boost from Novo Nordisk A/S’s previous Semi-Annual dividend of $0.22. The ex-dividend date was Friday, March 22nd. This represents a yield of 0.9%. Novo Nordisk A/S’s payout ratio is presently 49.17%.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.